November 20, 2026

Sysmex says Japan approves blood test for Alzheimer's marker

The test kit uses a small amount of the patient's blood to measure amyloid beta accumulation in the brain, allowing for earlier diagnosis and treatment

Sysmex says Japan approves blood test for Alzheimer's marker
The Food and Drug Administration on Monday, Jun 7, 2021, approved aducanumab, the first new medication for Alzheimer’s disease in nearly two decades, a contentious decision, made despite opposition from the agency’s independent advisory committee and some Alzheimer’s experts who said there was not enough evidence that the drug can help patients.

Reuters

Published : 22 Dec 2022, 03:03 PM

Updated : 22 Dec 2022, 03:02 PM

Japan's Sysmex Corp said on Thursday it had received regulatory approval in Japan for a blood test to detect amyloid beta in the brain, a characteristic of Alzheimer's disease.

The company developed the test with Japanese drugmaker Eisai Co and gained approval from regulators on Dec 19, it said in a statement.

The test kit uses a small amount of the patient's blood to measure amyloid beta accumulation in the brain, allowing for earlier diagnosis and treatment.

Sysmex, a maker of medical equipment and clinical tests, said it was preparing for market introduction as soon as possible.

Eisai and its US partner Biogen Inc BIIB.O are planning to seek full approval of their experimental Alzheimer's drug lecanemab in the United States, Europe and Japan next year.

Related Stories